Influence of variations across the MMP-1 and-3 genes on the serum levels of MMP-1 and-3 and disease activity in rheumatoid arthritis

Genes and Immunity

Volumn 13, Issue 1, 2012, Pages 29-37

  Chen, Y ^a,b   Nixon, N B ^b   Dawes, P T ^b   Mattey, D L ^a,b  

^a KEELE UNIVERSITY   (United Kingdom)

^b HAYWOOD HOSPITAL   (United Kingdom)

Author keywords

disease activity; matrix metalloproteinase; polymorphism; rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GENOMIC DNA; INTERSTITIAL COLLAGENASE; RHEUMATOID FACTOR; STROMELYSIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; DISEASE COURSE; DISEASE DURATION; DNA EXTRACTION; FEMALE; FOLLOW UP; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADULT; AGED; ARTHRITIS, RHEUMATOID; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84855972119     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2011.46     Document Type: Article

References (51)

1. MacNaul KL, Chartrain N, Lark M, Tocci MJ. Hutchinson. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem 1990; 265: 17238-17245.
2. Konttinen YT, Lindy O, Suomalainen K, Ritchlin C, Saari H, Vauhkonen M et al. Substrate specificity and activation mechanisms of collagenase from human rheumatoid synovium. Matrix 1991; 11: 395-403.
3. Gravallese EM, Darling JM, Ladd AL, Katz JN, Glimcher LH. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum 1991; 34: 1076-1084.
4. Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999; 58: 691-697. (Pubitemid 29517255)
5. Cunnane G, FitzGerald O, Hummel KM, Youssef PP, Gay RE, Gay S et al. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum 2001; 44: 1744-1753. (Pubitemid 32758219)
6. Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum 1992; 35: 35-42.
7. Taylor DJ, Cheung NT, Dawes PT. Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 1994; 53: 768-772. (Pubitemid 24347507)
8. Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T. Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 1994; 13: 228-233. (Pubitemid 24199148)
9. Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1) and MMP-1/TIMP-1 complex in rheumatic disease. Correlations with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999; 26: 251-258. (Pubitemid 29066724)
10. So A, Chamot M, Peclat V, Gerster J-C. Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not erosive status. Rheumatol 1999; 38: 407-410. (Pubitemid 29507123)
11. Cheung NT, Dawes PT, Poulton KV, Ollier WE, Taylor DJ, Mattey DL. High serum levels of pro-matrix metalloproteinase-are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis. J Rheumatol 2000; 27: 882-887. (Pubitemid 30389741)
12. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000; 43: 852-858.
13. Cunnane G, FitzGerald O, Beeton C, Cawston TE, Bresnihan B. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinase 1 in rheumatoid arthritis. Arthritis Rheum 2001; 44: 2263-2274. (Pubitemid 32977494)
14. Klimiuk PA, Sierakowski S, Latsiewicz R, Cylwik B, Skowronski J, Chwiecko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology 2002; 41: 78-87. (Pubitemid 34537925)
15. Green MJ, Gough AKS, Devlin J, Smith J, Astin P, Taylor D et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 2003; 42: 83-88. (Pubitemid 36131572)
16. Tchetverikov I, Ronday HK, vanEl B, Kiers GH, Verzijl N, TeKoppele JM et al. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63: 881-883. (Pubitemid 38850466)
17. Fiedorczyk M, Klimiuk PA, Sierakowski S, Gindzienska-Sieskiewicz E, Chwiecko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J Rheumatol 2006; 33: 1523-1529. (Pubitemid 44168822)
18. Ates A, Turkcapar N, OlmezU, Tiryaki O, Duzgun N, Uguz E et al. Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers. Rheumatol Int 2007; 27: 715-722. (Pubitemid 46716732)
19. Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Kamatani N et al. Elevation of serum matrix metalloproteinase-as a predictive marker for the long term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol 2007; 17: 403-408. (Pubitemid 47593489)
20. Constantin A, Lauwers-Cances V, Navaux F, Abbal M, van Meerwijk J, Mazieres B et al. Collagenase-1 (MMP-1) and HLA-DRB1 gene polymorphisms in rheumatoid arthritis: a prospective longitudinal study. J Rheumatol 2002; 29: 15-20. (Pubitemid 34041852)
21. Constantin A, Lauwers-Cances V, Navaux F, Abbal M, van Meerwijk J, Mazieres B et al. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: Association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum 2002; 46: 1754-1762. (Pubitemid 34774506)
22. Lee YH, Kim HJ, Rho YH, Choi SJ, Ji JD, Song GG. Functional polymorphisms in matrix metalloproteinase-1 and monocyte chemoattractant protein-1in rheumatoid arthritis. Scand J Rheumatol 2003; 32: 235-239. (Pubitemid 37266964)
23. Mattey DL, Nixon NB, Dawes PT, Ollier WE, Hajeer AH. Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis. Genes Immun 2004; 5: 147-149. (Pubitemid 38967645)
24. Dörr S, Lechtenböhmer N, Rau R, Herborn G,Wagner U,Mü ller-Myhsok B et al. Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritis. Arthritis Res Ther 2004; 6: 199-207.
25. Nemec P, Pavkova-Goldbergova M, Gatterova J, Vasku A, Soucek M. Association of the 5A/6A promoter polymorphism of the MMP-3 gene with the radiographic progression of rheumatoid arthritis. Ann NY Acad Sci 2007; 1110: 166-176. (Pubitemid 350054764)
26. Ye S, Patodi N,Walker-Bone K, Reading I, Cooper C, Dennison E. Variation in the matrix metalloproteinase-3,-7, 12 and-13 genes is associated with functional status in rheumatoid arthritis. Int J Immunogenet 2007; 34: 81-85. (Pubitemid 46435094)
27. Tsukahara S, Shinozaki M, Ikari K, Mochizuki T, Inoue E, Tomatsu T et al. Effect of matrix metalloproteinase-3 functional SNP on serum matrix metalloproteinase-3 level and outcome measures in Japanese RA patients. Rheumatology 2008; 47: 41-44. (Pubitemid 350286259)
28. Scherer Sabrina, de Souza TB, de Paoli J, Brenol CV, Xavier RM, Brenol JC et al. Matrix metalloproteinase gene polymorphism in patients with rheumatoid arthritis. Rheumatol Int 2010; 30: 369-373.
29. Cheng YC, Kao WHL, Mitchell BD, O'Connell JR, Shen H, McArdle PF et al. Genome-wide association scan identifies variants near matrix metalloproteinase (MMP) genes on chromosome 11q21-22 strongly associated with serum MMP-1 levels. Circ Cardiovasc Genet 2009; 2: 329-337.
30. Beyzade S, Zhang SL, Wong YK, Day IN, Eriksson P, Ye S. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol 2003; 41: 2130-2137. (Pubitemid 36724257)
31. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The ARA 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324. (Pubitemid 18091653)
32. Rutter JL, Mitchell TI, Butticé G, Meyers J, Gusella JF, Ozelius LJ et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998; 58: 5321-5325. (Pubitemid 28551108)
33. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996; 271: 13055-13060. (Pubitemid 26175880)
34. Zhu CY, Odeberg J, Hamsten A, Eriksson P. Allele-specific MMP-3 transcription under in vivo conditions. Biochem Biophys Res Commun 2006; 348: 1150-1156. (Pubitemid 44233533)
35. Samnegard A, Silveira A, Lundman P, Boquist S, Odeberg J, Hulthe J et al. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 1612 5A/6A promoter genotype and associated myocardial infarction. J Intern Med 2005; 258: 411-419. (Pubitemid 41546556)
36. White AJ, Duffy SJ, Walton AS, Ng JF, Rice GE, Mukherjee S et al. Matrix metalloproteinase-3 and coronary remodeling: Implications for unstable coronary diseae. Cardiovasc Res 2007; 75: 813-820. (Pubitemid 47238734)
37. Ghaderian SM, Akbarzadeh NR, Tabatabaei Panah AS. Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron Artery Dis 2010; 21: 330-335.
38. Souslova V, Townsend PA, Mann J, van der Loos CM, Motterle A, D'Acquisto F et al. Allele specific regulation of matrix metalloproteinase-3 gene by transcription factor NKkappaB. PLoS One 2010; 5: e9902.
39. Cao Z, Li C, Xiang J. Effect of matrix metalloproteinase-1 promoter genotype on interleukin-1beta-induced metalloproteinase production in human periodontal ligament cells. J Periodontal Res 2010; 45: 109-115.
40. Affara M, Dunmore BJ, Sanders DA, Johnson N, Print CG, Charnock-Jones DS. MMP1 bimodal expression and differential response to inflammatory mediators is linked to promoter polymorphisms. BMC Genomics 2011; 12: 43.
41. Repeke CE, Trombone AP, Ferreira Jr SB, Cardoso CR, Silviera EM, Martins JrWet al. Strong and persistent microbial and inflammatory stimuli overcome the genetic predisposition to higher matrix metalloproteinase-1 (MMP-1) expression: a mechanistic explanation for the lack of association of MMP1-1607 single nucleotide polymorphism genotypes with MMP-1 expression in chronic periodontitis lesions. J Clin Periodontol 2009; 36: 726-738.
42. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48.
43. Fries J, Spitz P, Young D. Dimensions of health outcome: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9: 789-793.
44. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 2001; 61: 7825-7829. (Pubitemid 33049371)
45. Shibata N, Ohnuma T, Higashi S, Usui C, Ohkubo T, Kitajima A et al. Genetic association between matrix metalloproteinase MMP-9 and MMP-3 polymorphisms and Japanese sporadic Alzheimer's disease. Neurobiol Aging 2005; 26: 1011-1014. (Pubitemid 40312664)
46. Gnasso A, Motti C, Irace C, Carallo C, Liberatoscioli L, Bernardini S et al. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 2000; 20: 1600-1605. (Pubitemid 30353894)
47. Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up-regulation of proinflammatory cytokines. Ann Rheum Dis 2007; 66: 712-719. (Pubitemid 46846688)
48. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265. (Pubitemid 40202029)
49. Lewontin RC. The interaction of selection and linkage. 1. General considerations: heterotic models. Genetics 1964; 49: 49-67.
50. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995; 12: 921-927.
51. Lin DY, Zeng D, Millikan R. Maximum likelihood estimation of haplotype effects and haplotype-environment interactions in association studies. Genet Epidemiol 2005; 29: 299-312. (Pubitemid 41720949)